On January 9, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra convened a virtual meeting with pharmacy leaders, pharmacy benefit managers, and insurers, emphasizing the critical need for equitable access to COVID-19 therapeutics. Secretary Becerra reiterated the commitment of HHS to collaborate with these stakeholders to ensure that all Americans have access to essential treatments without facing undue financial burdens. During the discussion, Secretary Becerra emphasized that no patient should be burdened with the full out-of-pocket cost to access Paxlovid, a key therapeutic for combating COVID-19. He urged stakeholders to promptly notify HHS of any challenges or issues that arise concerning access to COVID-19 therapeutics. Furthermore, Secretary Becerra underscored HHS' unwavering dedication to facilitating seamless access to oral antivirals for COVID-19 patients and encouraged healthcare providers to play an active role in ensuring that patients experiencing difficulties accessing Paxlovid or Lagevrio are directed to the respective patient assistance programs. Emphasizing the importance of continued provider engagement and education, Secretary Becerra reiterated HHS' commitment to maintaining broad access to COVID-19 therapeutics.

Highlights

• Secretary Becerra emphasizes equitable access to COVID-19 therapeutics during a virtual meeting with key stakeholders.
• HHS reaffirms its commitment to collaborating with pharmacies, benefit managers, and insurers to ensure access to essential treatments without undue financial burden.
• Stakeholders are urged to promptly report any challenges regarding access to COVID-19 therapeutics to HHS.
• Secretary Becerra underscores the importance of healthcare providers guiding patients towards available patient assistance programs for therapeutics.
• HHS emphasizes continued provider engagement and education to maintain broad access to COVID-19 therapeutics.